SG11201907466QA - Immune checkpoint therapy - Google Patents
Immune checkpoint therapyInfo
- Publication number
- SG11201907466QA SG11201907466QA SG11201907466QA SG11201907466QA SG11201907466QA SG 11201907466Q A SG11201907466Q A SG 11201907466QA SG 11201907466Q A SG11201907466Q A SG 11201907466QA SG 11201907466Q A SG11201907466Q A SG 11201907466QA SG 11201907466Q A SG11201907466Q A SG 11201907466QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- antigen
- antibody
- pct
- specifically binds
- Prior art date
Links
- 108091008036 Immune checkpoint proteins Proteins 0.000 title abstract 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 abstract 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 abstract 2
- 102000000588 Interleukin-2 Human genes 0.000 abstract 2
- 108010002350 Interleukin-2 Proteins 0.000 abstract 2
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000025171 antigen binding proteins Human genes 0.000 abstract 1
- 108091000831 antigen binding proteins Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 07 September 2018 (07.09.2018) WIPO I PCT 0111111010 0111 °nolo OH mum oimIE (10) International Publication Number WO 2018/158314 Al (51) International Patent Classification: C07K 16/28 (2006.01) C07K 14/55 (2006.01) A61K 41/00 (2006.01) (21) International Application Number: PCT/EP2018/054925 (22) International Filing Date: 28 February 2018 (28.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17158412.1 28 February 2017 (28.02.2017) EP (72) Inventor; and (71) Applicant: KLEEF, Ralf [AT/AT]; Auhofstrasse 1, 1130 Vienna (AT). (74) Agent: SONN & PARTNER PATENTANWALTE; Riemergasse 14, 1010 Vienna (AT). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, = (54) Title: IMMUNE CHECKPOINT THERAPY Fig. 1B Fig. 1C Fig. 1D Fig. 1E (57) : Disclosed is (a) an antibody or an antigen-binding portion thereof that specifically binds to and inhibits Programmed Death-1 (PD-1) and/or an antibody or an antigen—binding protein portion thereof that specifically binds to and inhibits Programmed Death-L1 (PD-L1); (b) an antibody or an antigen-binding portion thereof that specifically binds to and inhibits Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4); and (c) Interleukin-2 (IL-2) for use in the treatment of a cancer patient, wherein the body core temperature of said patient is kept at a temperature of 39.0°C to 40.5°C, preferably of 39.5°C to 40.5°C for at least 5 h per day for at least 4, preferably at least 5, consecutive days. [Continued on next page] WO 2018/158314 Al MIDEDIM01101 DIDIREIDI311111101111111111111111111111111111111111111111 TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: — with international search report (Art. 21(3))
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17158412.1A EP3366703B1 (en) | 2017-02-28 | 2017-02-28 | Immune checkpoint therapy with hyperthermia |
| PCT/EP2018/054925 WO2018158314A1 (en) | 2017-02-28 | 2018-02-28 | Immune checkpoint therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201907466QA true SG11201907466QA (en) | 2019-09-27 |
Family
ID=58192184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201907466QA SG11201907466QA (en) | 2017-02-28 | 2018-02-28 | Immune checkpoint therapy |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20190352382A1 (en) |
| EP (2) | EP3366703B1 (en) |
| JP (1) | JP2020509090A (en) |
| CN (1) | CN110352199A (en) |
| AU (1) | AU2018228705A1 (en) |
| MX (1) | MX2019009823A (en) |
| RU (1) | RU2019130318A (en) |
| SG (1) | SG11201907466QA (en) |
| WO (1) | WO2018158314A1 (en) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000028813A1 (en) * | 1998-11-19 | 2000-05-25 | St. Elizabeth's Medical Center | Treatment of myelogenous leukemia |
| SK288274B6 (en) | 1998-12-23 | 2015-06-02 | Pfizer Inc. | Monoclonal antibody against CTLA-4, process for preparation thereof, pharmaceutical composition, cell line, isolated nucleic acid, host cell, transgenic mammal and use of monoclonal antibody |
| CN1371416B (en) | 1999-08-24 | 2012-10-10 | 梅达里克斯公司 | Human CTLA-4 antibodies and their uses |
| JP4619651B2 (en) * | 2001-06-01 | 2011-01-26 | コーネル・リサーチ・ファンデーション・インコーポレイテッド | Modified antibodies against prostate-specific membrane antigen and uses thereof |
| US7282479B2 (en) * | 2003-03-31 | 2007-10-16 | Ttc Co., Ltd. | Hyperthermia agent for malignant tumor comprising cytokine and magnetic fine particles |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| EP2982379A1 (en) | 2005-07-01 | 2016-02-10 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| MX368507B (en) | 2012-05-15 | 2019-10-07 | Bristol Myers Squibb Co | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling. |
| EA201690912A1 (en) * | 2013-11-05 | 2016-10-31 | Когнейт Биосервисис, Инк. | COMBINATION INHIBITORS OF CONTROL POINTS AND THERAPEUTIC REMEDIES FOR THE TREATMENT OF CANCER |
| TWI680138B (en) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | Human antibodies to pd-l1 |
| KR20240144452A (en) * | 2014-03-05 | 2024-10-02 | 브리스톨-마이어스 스큅 컴퍼니 | Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent |
-
2017
- 2017-02-28 EP EP17158412.1A patent/EP3366703B1/en active Active
-
2018
- 2018-02-28 MX MX2019009823A patent/MX2019009823A/en unknown
- 2018-02-28 US US16/481,323 patent/US20190352382A1/en not_active Abandoned
- 2018-02-28 RU RU2019130318A patent/RU2019130318A/en unknown
- 2018-02-28 CN CN201880014551.XA patent/CN110352199A/en active Pending
- 2018-02-28 JP JP2019568804A patent/JP2020509090A/en active Pending
- 2018-02-28 AU AU2018228705A patent/AU2018228705A1/en not_active Abandoned
- 2018-02-28 SG SG11201907466QA patent/SG11201907466QA/en unknown
- 2018-02-28 WO PCT/EP2018/054925 patent/WO2018158314A1/en active Search and Examination
- 2018-02-28 EP EP18706538.8A patent/EP3589653A1/en active Pending
-
2021
- 2021-03-17 US US17/204,564 patent/US20210214428A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3589653A1 (en) | 2020-01-08 |
| JP2020509090A (en) | 2020-03-26 |
| EP3366703A1 (en) | 2018-08-29 |
| US20190352382A1 (en) | 2019-11-21 |
| RU2019130318A3 (en) | 2021-06-07 |
| US20210214428A1 (en) | 2021-07-15 |
| CN110352199A (en) | 2019-10-18 |
| RU2019130318A (en) | 2021-03-30 |
| AU2018228705A1 (en) | 2019-09-05 |
| WO2018158314A1 (en) | 2018-09-07 |
| EP3366703B1 (en) | 2019-04-03 |
| MX2019009823A (en) | 2020-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201907867TA (en) | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine | |
| SG11201910134SA (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| SG11201909081YA (en) | Anti-ilt4 antibodies and antigen-binding fragments | |
| SG11201903359RA (en) | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma | |
| SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
| SG11201809793UA (en) | Tl1a antibodies and uses thereof | |
| SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201908971RA (en) | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene | |
| SG11201905699XA (en) | Anti-icos agonist antibodies and uses thereof | |
| SG11201808724SA (en) | Anti-tim-3 antibodies and compositions | |
| SG11201907451XA (en) | Substituted imidazo-quinolines as nlrp3 modulators | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201908919XA (en) | Combination therapies targeting pd-1, tim-3, and lag-3 | |
| SG11201810883TA (en) | Combination therapy | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201811490XA (en) | Cd3 binding antibodies | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201900809TA (en) | Combination steerable catheter and systems | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
| SG11201810801QA (en) | Brain delivery protein | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof |